ARDX
Ardelyx, Inc. NASDAQ Listed Jun 19, 2014$6.98
After hrs
$6.74
-0.59%
Mkt Cap $1.7B
52w Low $3.21
72.6% of range
52w High $8.40
50d MA $6.11
200d MA $6.01
P/E (TTM)
-26.5x
EV/EBITDA
-53.1x
P/B
9.9x
Debt/Equity
1.3x
ROE
-36.9%
P/FCF
-32.0x
RSI (14)
—
ATR (14)
—
Beta
0.66
50d MA
$6.11
200d MA
$6.01
Avg Volume
3.6M
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
400 Fifth Avenue · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.13 | -0.15 | -15.4% | 6.33 | -5.2% | +8.7% | +15.3% | +12.6% | +12.2% | +10.3% | — |
| Feb 19, 2026 | AMC | 0.02 | 0.02 | +0.0% | 6.74 | -3.7% | -15.0% | -14.7% | -2.7% | -2.7% | -1.6% | — |
| Oct 30, 2025 | AMC | -0.06 | -0.00 | +93.3% | 5.01 | +28.3% | +21.0% | +18.2% | +11.8% | +18.8% | +12.8% | — |
| Aug 4, 2025 | AMC | -0.13 | -0.08 | +38.5% | 4.39 | +15.7% | +16.9% | +18.5% | +17.1% | +18.7% | +23.0% | — |
| May 1, 2025 | AMC | -0.10 | -0.17 | -70.0% | 5.47 | -26.0% | -24.5% | -31.6% | -27.8% | -32.4% | -33.5% | — |
| Feb 20, 2025 | AMC | 0.02 | 0.02 | +0.0% | 5.72 | +0.2% | -11.5% | -10.3% | -9.4% | -10.8% | -8.7% | — |
| Oct 31, 2024 | AMC | -0.05 | -0.00 | +93.2% | 5.87 | +2.0% | +3.7% | +0.3% | -2.6% | +10.6% | +8.7% | — |
| Aug 1, 2024 | AMC | -0.10 | -0.07 | +30.0% | 5.50 | +2.7% | +10.0% | +6.0% | +10.5% | +0.9% | +6.7% | — |
| May 2, 2024 | AMC | -0.13 | -0.11 | +15.4% | 6.79 | +23.1% | +28.4% | +34.8% | +37.1% | +24.9% | +18.7% | — |
| Feb 22, 2024 | AMC | -0.09 | -0.12 | -33.3% | 8.82 | -7.5% | -1.6% | +5.3% | +9.6% | +7.3% | +5.7% | — |
| Oct 31, 2023 | AMC | -0.11 | 0.03 | +127.3% | 3.95 | +0.0% | -0.3% | +1.5% | +1.8% | +1.3% | +3.0% | — |
| Aug 2, 2023 | AMC | -0.12 | -0.08 | +33.3% | 4.04 | +0.0% | -1.0% | -3.2% | -7.2% | -4.0% | -2.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23 | Wedbush | Maintains | Outperform → Outperform | — | $5.73 | $5.66 | -1.2% | +0.3% | +14.5% | +14.5% | +15.7% | +14.3% |
| Feb 20 | BTIG | Maintains | Buy → Buy | — | $6.74 | $6.49 | -3.7% | -15.0% | -14.7% | -2.7% | -2.7% | -1.6% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.74 | $6.49 | -3.7% | -15.0% | -14.7% | -2.7% | -2.7% | -1.6% |
| Jan 29 | BTIG | Maintains | Buy → Buy | — | $7.86 | $7.89 | +0.4% | -0.1% | -2.2% | -0.9% | -1.5% | -6.1% |
| Jan 21 | Wedbush | Maintains | Outperform → Outperform | — | $7.76 | $7.79 | +0.4% | +3.0% | +2.2% | +0.1% | +0.5% | +1.7% |
| Jan 9 | BTIG | Maintains | Buy → Buy | — | $7.00 | $7.30 | +4.3% | +10.6% | +5.1% | +0.6% | -1.6% | +0.6% |
| Jan 9 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.00 | $7.30 | +4.3% | +10.6% | +5.1% | +0.6% | -1.6% | +0.6% |
| Jan 9 | Citigroup | Maintains | Buy → Buy | — | $7.00 | $7.30 | +4.3% | +10.6% | +5.1% | +0.6% | -1.6% | +0.6% |
| Nov 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.92 | $5.84 | -1.4% | -5.4% | +0.5% | -4.6% | -5.6% | -4.6% |
| Nov 3 | Citigroup | Maintains | Buy → Buy | — | $6.06 | $6.07 | +0.2% | -2.3% | -7.6% | -1.8% | -6.8% | -7.8% |
| Oct 31 | TD Cowen | Maintains | Buy → Buy | — | $5.01 | $6.43 | +28.3% | +21.0% | +18.2% | +11.8% | +18.8% | +12.8% |
| Aug 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.13 | $5.13 | +0.0% | +1.4% | +0.2% | +1.6% | +5.3% | +9.2% |
| Aug 5 | Raymond James | Maintains | Outperform → Outperform | — | $4.39 | $5.08 | +15.7% | +16.9% | +18.5% | +17.1% | +18.7% | +23.0% |
| Aug 5 | Wedbush | Maintains | Outperform → Outperform | — | $4.39 | $5.08 | +15.7% | +16.9% | +18.5% | +17.1% | +18.7% | +23.0% |
| May 2 | Citigroup | Maintains | Buy → Buy | — | $5.47 | $4.05 | -26.0% | -24.5% | -31.6% | -27.8% | -32.4% | -33.5% |
| Feb 21 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $5.72 | $5.73 | +0.2% | -11.5% | -10.3% | -9.4% | -10.8% | -8.7% |
| Feb 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.72 | $5.73 | +0.2% | -11.5% | -10.3% | -9.4% | -10.8% | -8.7% |
| Jan 27 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.52 | $5.52 | +0.0% | -0.9% | -0.5% | -0.7% | -2.9% | -2.9% |
| Jan 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.35 | $5.33 | -0.4% | -3.6% | -6.4% | -8.2% | -5.6% | +3.0% |
| Jan 2 | Jefferies | Maintains | Buy → Buy | — | $5.07 | $5.03 | -0.8% | +1.0% | -2.0% | -1.4% | +6.7% | +5.3% |
| Nov 11 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $5.07 | $4.89 | -3.6% | -3.6% | -9.5% | -11.2% | -7.1% | -2.0% |
| Nov 4 | Citigroup | Maintains | Buy → Buy | — | $6.09 | $5.96 | -2.1% | -3.3% | -6.1% | +6.6% | +4.8% | -16.7% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.87 | $5.99 | +2.0% | +3.7% | +0.3% | -2.6% | +10.6% | +8.7% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.05 | $5.45 | -9.9% | -3.6% | +0.5% | -8.3% | -3.0% | -5.8% |
| Aug 2 | Wedbush | Maintains | Outperform → Outperform | — | $5.50 | $5.65 | +2.7% | +10.0% | +6.0% | +10.5% | +0.9% | +6.7% |
| Aug 2 | Citigroup | Maintains | Buy → Buy | — | $5.50 | $5.65 | +2.7% | +10.0% | +6.0% | +10.5% | +0.9% | +6.7% |
| Jul 18 | Wedbush | Maintains | Outperform → Outperform | — | $5.75 | $5.80 | +0.9% | -4.5% | -4.2% | -0.9% | -1.0% | -2.3% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.75 | $5.80 | +0.9% | -4.5% | -4.2% | -0.9% | -1.0% | -2.3% |
| Jul 3 | Citigroup | Maintains | Buy → Buy | — | $5.28 | $5.53 | +4.7% | +0.8% | +0.2% | +3.2% | +5.3% | +5.3% |
| May 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.44 | $7.33 | -1.5% | -9.3% | -7.3% | -11.2% | -8.9% | -7.8% |
| May 24 | Wedbush | Maintains | Outperform → Outperform | — | $7.44 | $7.33 | -1.5% | -9.3% | -7.3% | -11.2% | -8.9% | -7.8% |
| May 3 | Citigroup | Maintains | Buy → Buy | — | $6.79 | $8.36 | +23.1% | +28.4% | +34.8% | +37.1% | +24.9% | +18.7% |
| May 3 | Wedbush | Maintains | Outperform → Outperform | — | $6.79 | $8.36 | +23.1% | +28.4% | +34.8% | +37.1% | +24.9% | +18.7% |
| Apr 17 | Wedbush | Maintains | Outperform → Outperform | — | $6.71 | $6.83 | +1.8% | -2.4% | -4.0% | -3.4% | -3.0% | -4.8% |
| Feb 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.82 | $8.16 | -7.5% | -1.6% | +5.3% | +9.6% | +7.3% | +5.7% |
| Feb 23 | Wedbush | Maintains | Outperform → Outperform | — | $8.82 | $8.16 | -7.5% | -1.6% | +5.3% | +9.6% | +7.3% | +5.7% |
| Jan 12 | Wedbush | Maintains | Outperform → Outperform | — | $8.72 | $8.81 | +1.0% | +3.6% | +0.7% | -2.3% | -7.8% | -5.0% |
| Jan 10 | Citigroup | Maintains | Buy → Buy | — | $9.10 | $9.18 | +0.9% | -0.2% | -4.2% | -0.8% | -3.5% | -6.4% |
| Jan 9 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $8.18 | $8.17 | -0.1% | +11.2% | +11.0% | +6.6% | +10.4% | +7.3% |
| Dec 1 | Wedbush | Maintains | Outperform → Outperform | — | $4.51 | $4.50 | -0.2% | +5.5% | +10.0% | +11.3% | +14.0% | +17.5% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.95 | $3.95 | +0.0% | -0.3% | +1.5% | +1.8% | +1.3% | +3.0% |
| Sep 13 | Wedbush | Maintains | Outperform → Outperform | — | $4.83 | $4.86 | +0.6% | -5.0% | -3.5% | -5.8% | -13.7% | -17.0% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.73 | $4.77 | +0.8% | +2.1% | -3.0% | -1.5% | -3.8% | -11.8% |
| Aug 25 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $3.51 | $3.69 | +5.1% | +12.3% | +21.1% | +19.7% | +20.8% | +21.4% |
| Aug 3 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $4.04 | $4.04 | +0.0% | -1.0% | -3.2% | -7.2% | -4.0% | -2.0% |
| Apr 17 | Wedbush | Maintains | Outperform → Outperform | — | $4.71 | $4.67 | -0.8% | +4.5% | +3.8% | +4.0% | +1.5% | +5.1% |
| Mar 3 | Wedbush | Upgrade | Neutral → Outperform | — | $2.89 | $3.40 | +17.6% | +32.2% | +34.9% | +36.3% | +40.8% | +32.2% |
| Dec 30 | Citigroup | Maintains | Buy → Buy | — | $2.53 | $2.59 | +2.4% | +12.6% | +5.9% | +11.1% | +8.7% | +13.4% |
| Nov 17 | Piper Sandler | Upgrade | Neutral → Overweight | — | $1.22 | $1.97 | +61.5% | +41.0% | +70.5% | +69.7% | +51.6% | +45.1% |
| May 19 | Piper Sandler | Maintains | Neutral → Neutral | — | $0.66 | $0.68 | +2.6% | +2.6% | -0.8% | -4.3% | -9.6% | -8.1% |
No insider trades available.
Data updated apr 24, 2026 6:48pm
· Source: massive.com